Stryker Corporation $SYK Shares Acquired by State Street Corp

Stryker logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street increased its Stryker stake by 1.7% in the third quarter, adding 266,992 shares and bringing its holding to about 15.8 million shares, worth approximately $4.36 billion. Institutional investors collectively own 77.09% of the company.
  • Stryker’s latest quarterly results fell short of expectations: earnings were $3.52 per share versus $3.55 forecast, while revenue of $6.52 billion missed the $6.62 billion estimate. Revenue nevertheless grew 7.6% year over year.
  • Analysts maintain a “Moderate Buy” consensus with a $343.77 average price target; 21 rate the stock a Buy and seven a Hold. Director Ronda Stryker also sold 550,000 shares for about $178.9 million.
  • MarketBeat previews top five stocks to own in December.

State Street Corp increased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,799,557 shares of the medical technology company's stock after acquiring an additional 266,992 shares during the period. State Street Corp owned approximately 4.15% of Stryker worth $4,364,738,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of SYK. International Assets Investment Management LLC lifted its holdings in Stryker by 1,432.8% during the third quarter. International Assets Investment Management LLC now owns 25,000 shares of the medical technology company's stock valued at $6,885,000 after purchasing an additional 23,369 shares in the last quarter. Amundi increased its stake in shares of Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company's stock worth $392,402,000 after purchasing an additional 192,447 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Stryker by 8.2% during the second quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company's stock worth $270,642,000 after purchasing an additional 65,333 shares in the last quarter. Veritas Asset Management LLP purchased a new stake in shares of Stryker during the second quarter worth about $168,057,000. Finally, Bank of America Corp DE acquired a new position in shares of Stryker during the 2nd quarter worth about $1,404,284,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Price Performance

SYK stock opened at $309.91 on Friday. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The firm has a market capitalization of $117.98 billion, a PE ratio of 33.00, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78. The business has a 50 day simple moving average of $295.66 and a 200-day simple moving average of $321.39.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The business's quarterly revenue was up 7.6% on a year-over-year basis. During the same period last year, the firm posted $3.19 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In other news, Director Ronda Stryker sold 550,000 shares of the business's stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the transaction, the director owned 1,701,375 shares of the company's stock, valued at approximately $553,491,315. The trade was a 24.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.60% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SYK shares. UBS Group lowered their price objective on Stryker from $400.00 to $382.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. Deutsche Bank decreased their target price on Stryker from $315.00 to $275.00 and set a "hold" rating on the stock in a research report on Friday, October 30th. Raymond James Financial reaffirmed an "outperform" rating and issued a $323.00 price target (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday, August 13th. Finally, Barclays reduced their price objective on Stryker from $375.00 to $365.00 and set an "overweight" rating for the company in a research note on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $343.77.

View Our Latest Analysis on SYK

About Stryker

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company's products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines